publication date: Jun. 6, 2014

In Brief
Georgetown, Theurer Form Collaboration;
Hopkins to Develop Bladder Cancer Institute


The Regional Immunotherapy Discovery Program will focus on a new approach that combines cancer immunotherapy and bone marrow stem cell transplantation. Both centers offer transplant programs that manipulate the immune cells via both allogeneic and autologous transplants to treat patients with blood cancers.

“By combining these two strategies in attacking cancer, we believe it’s possible to optimize the true promise of immunotherapy and extend treatment options to specific patient populations,” says André Goy, chairman of JTCC. “This approach is only now emerging at a very limited number of cancer centers in the U.S.”

One example of the new strategy would be to combine an immunotherapy drug such as a PD-1 inhibitor, which selectively unleashes immune cells, with an adoptive cellular therapy to assist reconstitution of the immune system following immune cell-depleting chemotherapy against blood cancer.

Michael Atkins, deputy director of Georgetown Lombardi, and Andrew Pecora, president of RCCA, will lead the program, which builds on an oncology affiliation that Georgetown Lombardi and JTCC established in 2013. 

As part of the affiliation, the two institutions are working toward becoming an NCI-recognized consortium center, in which investigators from separate but collaborating scientific institutions contribute actively to the development and actualization of a specific cancer research agenda.

THE JOHNS HOPKINS UNIVERSITY received a $15 million pledge to help create a new bladder cancer institute. 

The gift, from Baltimore-area commercial real estate developer … Continue reading 40-23 The Cancer Letter In Brief

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.